Literature DB >> 33845198

Xpert MTB/RIF Ultra enhances tuberculous pleurisy diagnosis for patients with unexplained exudative pleural effusion who underwent a pleural biopsy via thoracoscopy: a prospective cohort study.

Shan Gao1, Chong Wang2, Xia Yu3, Tianlu Teng4, Yuanyuan Shang5, Junnan Jia6, Lingling Dong7, Liping Zhao8, Shuku Liu9, Naihui Chu10, Hairong Huang11.   

Abstract

INTRODUCTION: To evaluate the performance of Xpert MTB/RIF Ultra (Xpert-Ultra) in testing pleural tissue and fluid collected by medical thoracoscopy among patients with unexplained exudative pleural effusion.
METHODS: Patients with an undiagnosed exudative pleural effusion were recruited prospectively and consecutively. Pleural tissue and fluid was collected by medical thoracoscopy and subjected to culture, Xpert MTB/RIF (Xpert) and Xpert-Ultra assays. Histopathological examination was also performed with the tissue and used as the major reference.
RESULTS: Sixty one patients including 27 tuberculosis (TB) pleurisy, 15 malignancy and 19 other chronic infection cases were enrolled. The sensitivity, specificity, positive predict value and negative predict value of Xpert-Ultra for TB diagnosis were 85.19% (23/27), 97.06% (33/34), 95.83% (23/24) and 89.19% (33/37), respectively. Xpert-Ultra testing with the biopsy tissue alone had an equivalent diagnostic capacity to that of pathological examination for the diagnosis of confirmed TB cases. By combining pathological examination with Xpert-Ultra for biopsy, the percentage of confirmed TB cases increased greatly i.e. 92.59% (25/27). "Trace" positive outcome of Xpert-Ultra was highly supportive of TB diagnosis for both biopsy tissue and pleural fluid examinations.
CONCLUSION: With the specimens collected by medical thoracoscopy, Xpert-Ultra assay presented high value in identifying tuberculous among pleurisy patients who had difficulties in etiological diagnosis.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  Tuberculosis; Xpert MTB/RIF Ultra; medical thoracoscopy; unexplained exudative pleural effusion

Year:  2021        PMID: 33845198     DOI: 10.1016/j.ijid.2021.04.011

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  6 in total

1.  Evaluating the efficacy of stool sample on Xpert MTB/RIF Ultra and its comparison with other sample types by meta-analysis for TB diagnostics.

Authors:  Vishal Sharma; Anoop Singh; Mohita Gaur; Deepti Rawat; Anjali Yadav; Chanchal Kumar; Mandira Varma-Basil; Sheelu Lohiya; Vishal Khanna; Ashwani Khanna; Anil Chaudhry; Yogendra Singh; Richa Misra
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-05-04       Impact factor: 3.267

2.  Xpert MTB/RIF Ultra versus Xpert MTB/RIF for diagnosis of tuberculous pleural effusion: A systematic review and comparative meta-analysis.

Authors:  Ashutosh Nath Aggarwal; Ritesh Agarwal; Sahajal Dhooria; Kuruswamy Thurai Prasad; Inderpaul Singh Sehgal; Valliappan Muthu
Journal:  PLoS One       Date:  2022-07-11       Impact factor: 3.752

3.  Head-to-head comparison of the efficacy of Xpert MTB/RIF Ultra and Xpert MTB/RIF for the diagnosis of tuberculous pleurisy: A systematic review and meta-analysis.

Authors:  Wenfeng Yu; Yanqin Shen; Pengfei Zhu; Da Chen
Journal:  Medicine (Baltimore)       Date:  2022-05-20       Impact factor: 1.817

Review 4.  Rapid Molecular Diagnosis of Extra-Pulmonary Tuberculosis by Xpert/RIF Ultra.

Authors:  Laura Rindi
Journal:  Front Microbiol       Date:  2022-05-11       Impact factor: 6.064

5.  Accuracy of Xpert MTB/RIF assay for the diagnosis of tuberculous pleural effusion.

Authors:  Yi-Ran Qiu; Yu-Yan Chen; Xin-Ran Wu; Ya-Ping Li; Xun-Jie Cao; Zi-Yuan Yu; Min Lin; Qiu-Yin Li; Ji-Chun Chen; Xin Yin; Shu-Chang Weng; Xu-Guang Guo
Journal:  J Clin Lab Anal       Date:  2021-12-17       Impact factor: 2.352

6.  Diagnostic accuracy of adenosine deaminase for pleural tuberculosis in a low prevalence setting: A machine learning approach within a 7-year prospective multi-center study.

Authors:  Alberto Garcia-Zamalloa; Diego Vicente; Rafael Arnay; Arantzazu Arrospide; Jorge Taboada; Iván Castilla-Rodríguez; Urko Aguirre; Nekane Múgica; Ladislao Aldama; Borja Aguinagalde; Montserrat Jimenez; Edurne Bikuña; Miren Begoña Basauri; Marta Alonso; Emilio Perez-Trallero
Journal:  PLoS One       Date:  2021-11-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.